Nrx Pharmaceuticals Inc
(NQ:
NRXP
)
1.250
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 13, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
158
Open
1.250
Bid (Size)
1.270 (3)
Ask (Size)
1.310 (1)
Prev. Close
1.250
Today's Range
1.250 - 1.250
52wk Range
1.100 - 7.333
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Jonathan Javitt, CEO of NRx Pharmaceuticals Inc. (NASDAQ: NRXP), to Present at NobleCon20
November 13, 2024
Via
Investor Brand Network
HOPE Therapeutics Secures Financing For Ketamine Clinic Expansion
August 26, 2024
HOPE Therapeutics, Inc., a subsidiary of NRx Pharmaceuticals, Inc. (NASDAQ: NRXP),
Via
Benzinga
Performance
YTD
-74.95%
-74.95%
1 Month
-5.30%
-5.30%
3 Month
-32.80%
-32.80%
6 Month
-61.30%
-61.30%
1 Year
-64.29%
-64.29%
More News
Read More
Plans for New Acquisition of Clinics Generating $100 Million to Complement Progress on Accelerated Drug Approval for Bipolar Depression and Related Disorders: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
August 26, 2024
Via
Get News
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
Substantial Funding, Debt Resolution, HOPE Dividend, Successful Clinical Trial Towards Accelerated Drug Approval for Bipolar Depression: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
August 15, 2024
Via
Get News
Topics
Regulatory Compliance
Retirement
Exposures
Legal
Pension
Regulatory
NRXP Stock Earnings: NRX Pharmaceuticals Misses EPS for Q2 2024
August 14, 2024
Via
InvestorPlace
Alignment with FDA on Pediatric Study Plan and Accelerated Approval to Treat Bipolar Depression and Akathisia: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
July 30, 2024
Via
Get News
Exposures
Product Safety
Substantial Funding, Debt Resolution, HOPE Dividend, Successful Clinical Trial Towards Accelerated Drug Approval for Bipolar Depression: Nasdaq: NRXP
August 15, 2024
Via
PRLog
Topics
Regulatory Compliance
Exposures
Legal
Product Safety
Regulatory
Accelerated Approval to Treat Bipolar Depression and Akathisia Could Yield Over $150 in Revenue Per Share; Planned HOPE Subsidiary Spinoff to Continue: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
July 29, 2024
Via
Get News
NRx Pharmaceuticals Highlights Breakthrough Oral Antidepressant’s Efficacy in Reducing Suicidality in Bipolar Depression at ASCP June 2024 Meeting: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
June 10, 2024
Via
Get News
First Oral Antidepressant Clinically Demonstrated to Reduce Suicidality in Bipolar Depression with Data Supporting Accelerated Approval Process: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
May 28, 2024
Via
Get News
12 Health Care Stocks Moving In Thursday's Intraday Session
May 16, 2024
Via
Benzinga
NRXP Stock Earnings: NRX Pharmaceuticals Misses EPS for Q1 2024
May 14, 2024
Via
InvestorPlace
NRx Pharmaceuticals Eyes First Commercial Revenue in 2024, Announces Breakthroughs in Bi-Annual Milestone Update
May 08, 2024
Via
ACCESSWIRE
Final Clinical Trial Results Show Superior Safety and Efficacy for NRX-101; Plans to Seek Accelerated Approval for Bipolar Depression and Schizophrenia: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
May 06, 2024
Via
Get News
12 Health Care Stocks Moving In Monday's Intraday Session
May 06, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
May 01, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
April 30, 2024
Via
Benzinga
Gold Down Over 2%; 3M Profit Beats Expectations
April 30, 2024
Via
Benzinga
Why H&E Equipment Services Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
April 30, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
April 30, 2024
Via
Benzinga
Why Is NRx Pharmaceuticals Stock Falling After Data From Suicidal Bipolar Depression Study
April 30, 2024
Via
Benzinga
InvestorNewsBreaks – NRx Pharmaceuticals Inc. Releases Pricing of Public Offering, Expected to Result in Estimated $2M
April 22, 2024
Via
Investor Brand Network
Exposures
Product Safety
Nasdaq Down 0.5%; Lithium Americas Shares Slide
April 18, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
April 18, 2024
Via
Benzinga
Crude Oil Edges Lower; Bio-Path Holdings Shares Spike Higher
April 18, 2024
Via
Benzinga
Exposures
Fossil Fuels
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.